Studies on phytochemical, antioxidant, anti-inflammatory, hypoglycaemic and antiproliferative activities of Echinacea purpurea and Echinacea angustifolia extracts

Pharm Biol. 2017 Dec;55(1):649-656. doi: 10.1080/13880209.2016.1265989.

Abstract

Context: Echinacea (Asteraceae) is used because of its pharmacological properties. However, there are few studies that integrate phytochemical analyses with pharmacological effects.

Objective: Evaluate the chemical profile and biological activity of hydroalcoholic Echinacea extracts.

Materials and methods: Density, dry matter, phenols (Folin-Ciocalteu method), flavonoids (AlCl3 method), alkylamides (GC-MS analysis), antioxidant capacity (DPPH and ABTS methods), antiproliferative effect (SRB assay), anti-inflammatory effect (paw oedema assay, 11 days/Wistar rats; 0.4 mL/kg) and hypoglycaemic effect (33 days/Wistar rats; 0.4 mL/kg) were determined in three Echinacea extracts which were labelled as A, B and C (A, roots of Echinacea purpurea L. Moench; B, roots, leaves, flowers and seeds of Echinacea purpurea; C, aerial parts and roots of Echinacea purpurea and roots of Echinacea angustifolia DC).

Results: Extract C showed higher density (0.97 g/mL), dry matter (0.23 g/mL), phenols (137.5 ± 2.3 mEAG/mL), flavonoids (0.62 ± 0.02 mEQ/mL), and caffeic acid (0.048 mg/L) compared to A and B. A, B presented 11 alkylamides, whereas C presented those 11 and three more. B decreased the oedema (40%) on day 2 similar to indomethacin. A and C showed hypoglycaemic activity similar to glibenclamide. Antiproliferative effect was only detected for C (IC50 270 μg/mL; 8171 μg/mL; 9338 μg/mL in HeLa, MCF-7, HCT-15, respectively).

Discussion and conclusion: The difference in the chemical and pharmacological properties among extracts highlights the need to consider strategies and policies for standardization of commercial herbal extracts in order to guarantee the safety and identity of this type of products.

Keywords: Herbal; fingerprints; standardization.

MeSH terms

  • Alloxan
  • Animals
  • Anti-Inflammatory Agents / isolation & purification
  • Anti-Inflammatory Agents / pharmacology*
  • Antineoplastic Agents, Phytogenic / isolation & purification
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Antioxidants / isolation & purification
  • Antioxidants / pharmacology*
  • Benzothiazoles / chemistry
  • Biomarkers / blood
  • Biphenyl Compounds / chemistry
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Carrageenan
  • Cell Proliferation / drug effects*
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Echinacea / chemistry*
  • Echinacea / classification
  • Edema / chemically induced
  • Edema / prevention & control*
  • HeLa Cells
  • Humans
  • Hypoglycemic Agents / isolation & purification
  • Hypoglycemic Agents / pharmacology*
  • MCF-7 Cells
  • Male
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Phytochemicals / isolation & purification
  • Phytochemicals / pharmacology*
  • Phytotherapy
  • Picrates / chemistry
  • Plant Extracts / isolation & purification
  • Plant Extracts / pharmacology*
  • Plants, Medicinal
  • Rats, Wistar
  • Sulfonic Acids / chemistry
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents, Phytogenic
  • Antioxidants
  • Benzothiazoles
  • Biomarkers
  • Biphenyl Compounds
  • Blood Glucose
  • Hypoglycemic Agents
  • Phytochemicals
  • Picrates
  • Plant Extracts
  • Sulfonic Acids
  • 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid
  • Alloxan
  • Carrageenan
  • 1,1-diphenyl-2-picrylhydrazyl

Grants and funding

This work was supported by CONACyT; under Grant 248821 and UAM-PTC; under Grant 510.